Table 1 Patient Demographics and Clinical Characteristics
From: Insight into the current practice of ototoxicity monitoring during cisplatin therapy
| Characteristic | N (%) |
|---|---|
| Sex | |
| Male | 216 (60) |
| Female | 163 (40) |
| Malignancy type | |
| Breast | 3 (0.8) |
| Central Nervous System | 12 (3.2) |
| Gastrointestinal | 32 (8.4) |
| Gynecologic | 74 (19.5) |
| Head & Neck | 122 (32.2) |
| Hematologic | 3 (0.8) |
| Lung | 51 (13.5) |
| Sarcoma | 7 (1.8) |
| Skin | 5 (1.3) |
| Urologic | 70 (18.5) |
| Treatment intent | |
| Curative | 305 (80.5) |
| Palliative | 65 (17.2) |
| Unknown | 9 (2.3) |
| History of Prior Radiation to Head and Neck | |
| Yes | 16 (4.2) |
| No | 312 (82.3) |
| Unknown | 51 (13.5) |
| Concurrent Radiation Treatment | |
| Yes | 204 (53.8) |
| No | 175 (46.2) |
| History of Hearing Loss prior to treatment | |
| Yes | 104 (27.4) |
| No | 183 (48.3) |
| Unknown | 92 (24.3) |